Companies Jade Biosciences, Inc.
Jade Biosciences (AVTE): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Jade Biosciences, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers88th pct.Of 20 peer CEOs
CEO pay, last three years
- $1,364,396FY2024
- $9,799,759FY2025
CEO total pay was $9,799,759 in fiscal 2025, up from $1,364,396 in fiscal 2024.
FY2025: salary $621,970 · bonus $0 · stock awards $0 · option awards $8,779,876
Frequently asked questions
Who was the highest-paid executive at Jade Biosciences, Inc. in fiscal 2025?
As disclosed, Tom Frohlich (Chief Executive Officer, President and Director) was the highest-paid executive at Jade Biosciences, Inc. in fiscal 2025, with total compensation of $9,799,759.
How does Jade Biosciences, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Tom Frohlich's total compensation ranked at the 88th percentile of Jade Biosciences, Inc.'s disclosed peer group.
How much does Jade Biosciences, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Jade Biosciences, Inc. reported total board compensation of $317,700 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Tom Frohlich | $621,970 | $0 | $0 | $8,779,876 | $397,913 | $0 | $0 | $9,799,759 |
| Chief Executive Officer, President and Director | ||||||||
| Andrew King | 507,301 | 0 | 0 | 3,775,903 | 258,600 | 0 | 0 | 4,541,804 |
| President, Research and Development | ||||||||
| Bradford Dahms | 233,013 | 0 | 0 | 3,781,940 | 113,600 | 0 | 3,438 | 4,131,991 |
| Chief Financial Officer | ||||||||
| Timothy Noyes | 213,767 | 0 | 0 | 0 | 0 | 0 | 1,600,716 | 1,814,483 |
| Former Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Tom Frohlich | $9,799,759 | $1,364,396 | — | ↑ +8,435,363 |
| Andrew King | 4,541,804 | 751,605 | — | ↑ +3,790,199 |
| Bradford Dahms | 4,131,991 | — | — | — |
| Timothy Noyes | 1,814,483 | 3,391,536 | — | ↓ −1,577,053 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation program is designed to align the interests of executive officers and stockholders by making a significant portion of compensation 'at risk' based on performance, including short-term cash incentives and long-term equity incentives. The program is weighted toward long-term incentive compensation to discourage short-term risk taking and utilizes multi-year vesting requirements consistent with market practice and retention objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Bradford Dahms | OPTION | 2025-07-14 | — | — | 526,000 | — | $3,781,940 |
| Tom Frohlich | OPTION | 2025-01-29 | — | — | 1,060,732 | — | — |
| Tom Frohlich | OPTION | 2025-01-29 | — | — | 779,934 | — | — |
| Andrew King | OPTION | 2025-01-29 | — | — | 238,894 | — | — |
| Andrew King | OPTION | 2025-01-29 | — | — | 552,709 | — | — |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Bradford Dahms | $0 | $0 | $3,781,940 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Andrew King | Option | 18,964 | 0.31 | — |
| Andrew King | Option | 123,600 | 1.46 | — |
| Andrew King | Option | 184,147 | 6.03 | — |
| Andrew King | RSU | 229,907 | — | 3,547,465 |
| Bradford Dahms | Option | 526,000 | 9 | — |
| Andrew King | Option | 552,709 | 6.03 | — |
| Tom Frohlich | Option | 659,550 | 0.96 | — |
| Tom Frohlich | Option | 779,934 | 6.03 | — |
| Tom Frohlich | Option | 817,643 | 6.03 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Eric Dobmeier, J.DIndependent · Audit · Nominating and Corporate Governance | $55,688 | — | $171,247 | — | $0 | $226,935 |
| Erin LavelleIndependent · Audit (Chair) · Compensation | 41,175 | — | 171,247 | — | 0 | 212,422 |
| Lawrence Klein, Ph.DIndependent · Audit · Nominating and Corporate Governance (Chair) | 38,812 | — | 171,247 | — | 0 | 210,059 |
| Tomas KiselakIndependent · Compensation (Chair) | 35,100 | — | 171,247 | — | 0 | 206,347 |
| Christopher Cain, Ph.DIndependent · Compensation · Nominating and Corporate Governance | 34,425 | — | 171,247 | — | 0 | 205,672 |
| Mark IwickiIndependent · Departed during FY | 26,250 | — | 0 | — | 0 | 26,250 |
| Allison DorvalIndependent · Departed during FY | 25,000 | — | 0 | — | 0 | 25,000 |
| Habib J. DableIndependent · Departed during FY | 21,250 | — | 0 | — | 0 | 21,250 |
| Joshua Resnick, M.DIndependent · Departed during FY | 19,500 | — | 0 | — | 0 | 19,500 |
| David Grayzel, M.DIndependent · Departed during FY | 10,750 | — | 0 | — | 0 | 10,750 |
| Donald J. SantelIndependent · Departed during FY | 9,750 | — | 0 | — | 0 | 9,750 |
Board fee structure and ownership guideline
| Annual cash retainer | $35,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $317,700 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $317,700 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Jade Biosciences as a peer
Companies that benchmark against AVTE
1 company names AVTE as a compensation peer
- Edgewise Therapeutics, Inc.EWTXFY2025
Each company listed discloses AVTE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AVTE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
SLRN ACELYRIN, Inc.ALMS Alumis Inc.APGE Apogee Therapeutics, Inc.ATXS Astria Therapeutics, Inc.CRGX CARGO Therapeutics, Inc.CTNM Contineum Therapeutics, Inc.DNTH Dianthus Therapeutics, Inc.TRDA Entrada Therapeutics, Inc.JANX Janux Therapeutics, Inc.KYMR Kymera Therapeutics, Inc.KYTX Kyverna Therapeutics, Inc.LYEL Lyell Immunopharma, Inc.ORKA Oruka Therapeutics, Inc.PLRX Pliant Therapeutics, Inc.PRME Prime Medicine, Inc. Septerna Therapeutics, Inc.SYRE Spyre Therapeutics, Inc.THRD Third Harmonic Bio, Inc.UPB Upstream Bio, Inc.ZBIO Zenas BioPharma, Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Janux Therapeutics, Inc. | 2025 | David Campbell | $680,000 | $0 | $12,459,031 | $367,200 | $13,506,231 |
| 2 | Dianthus Therapeutics, Inc. | 2025 | Marino Garcia | 630,000 | 0 | 9,450,952 | 519,750 | 10,614,702 |
| 3 | Jade Biosciences, Inc. | 2025 | Tom Frohlich | 621,970 | 0 | 8,779,876 | 397,913 | 9,799,759 |
| 4 | Cargo Therapeutics, Inc. | 2024 | Gina Chapman | 630,800 | 0 | 8,155,520 | 363,800 | 9,300,120 |
| 5 | Kymera Therapeutics, Inc. | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 6 | Spyre Therapeutics, Inc. | 2025 | Cameron Turtle | 665,000 | 0 | 5,552,886 | 475,475 | 6,707,361 |
| 7 | Astria Therapeutics, Inc. | 2024 | Jill Milne | 637,868 | 0 | 5,637,078 | 318,934 | 6,604,416 |
| 8 | Alumis Inc. | 2025 | Martin Babler | 680,830 | 0 | 4,743,220 | 524,239 | 5,948,289 |
| 9 | Pliant Therapeutics, Inc. | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 10 | Zenas BioPharma, Inc. | 2025 | Leon Moulder | 520,000 | 0 | 3,769,200 | 371,800 | 4,661,000 |
| 11 | Upstream Bio, Inc. | 2025 | E. Rand Sutherland | 650,000 | 0 | 3,300,350 | 341,250 | 4,302,100 |
| 12 | Lyell Immunopharma, Inc. | 2025 | Lynn Seely | 690,173 | 186,806 | 2,907,551 | 414,000 | 4,222,265 |
| 13 | Prime Medicine, Inc. | 2025 | Allan Reine | 606,212 | 0 | 2,828,798 | 402,000 | 3,894,187 |
| 14 | Entrada Therapeutics, Inc. | 2025 | Dipal Doshi | 635,000 | 1,387,428 | 1,452,059 | 349,250 | 3,837,737 |
| 15 | Contineum Therapeutics, Inc. | 2025 | Carmine Stengone | 655,620 | 0 | 2,291,640 | 450,739 | 3,409,448 |
| 16 | Oruka Therapeutics, Inc. | 2025 | Lawrence Klein | 624,000 | 0 | 2,275,390 | 446,160 | 3,356,050 |
| 17 | Kyverna Therapeutics, Inc. | 2025 | Warner Biddle | 625,000 | 0 | 543,804 | 468,750 | 1,814,980 |
| 18 | Apogee Therapeutics, Inc. | 2025 | Michael Henderson | 700,000 | 0 | 0 | 591,500 | 1,291,500 |
| — | Acelyrin, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Third Harmonic Bio, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Jade Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Acelyrin, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Alumis Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Apogee Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Alpine Rewards |
| Astria Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Cargo Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Contineum Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Alpine |
| Dianthus Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Entrada Therapeutics, Inc. | not disclosed | not disclosed | No | Pay Governance |
| Janux Therapeutics, Inc. | 90% | not disclosed | not disclosed | FW Cook |
| Kymera Therapeutics, Inc. | 125% | not disclosed | No | Alpine Rewards |
| Kyverna Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon plc |
| Lyell Immunopharma, Inc. | 100% | not disclosed | No | Alpine |
| Oruka Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards LLC |
| Pliant Therapeutics, Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Pearl Meyer; Alpine Rewards |
| Prime Medicine, Inc. | 120% | not disclosed | not disclosed | Alpine Rewards |
| Spyre Therapeutics, Inc. | 130% | Option 100 | not disclosed | Alpine Rewards |
| Third Harmonic Bio, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Upstream Bio, Inc. | 52.5% | Option 100 | not disclosed | Alpine Rewards |
| Zenas BioPharma, Inc. | not disclosed | Option 100 | not disclosed | Alpine |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (41 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Tom Frohlich. DEF 14A, filed 2026-04-28. Section “SUMMARY COMPENSATION TABLE” · page 35. As printed: 9,799,759. View filing ↗
- Section 01, Andrew King. DEF 14A, filed 2026-04-28. Section “SUMMARY COMPENSATION TABLE” · page 35. As printed: 4,541,804. View filing ↗
- Section 01, Bradford Dahms. DEF 14A, filed 2026-04-28. Section “SUMMARY COMPENSATION TABLE” · page 35. As printed: 4,131,991. View filing ↗
- Section 01, Timothy Noyes. DEF 14A, filed 2026-04-28. Section “SUMMARY COMPENSATION TABLE” · page 35. As printed: 1,814,483. View filing ↗
- Section 03, Bradford Dahms OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Tom Frohlich OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Tom Frohlich OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew King OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew King OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Eric Dobmeier, J.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 226,935. View filing ↗
- Section 08, Erin Lavelle. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 212,422. View filing ↗
- Section 08, Lawrence Klein, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 210,059. View filing ↗
- Section 08, Tomas Kiselak. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 206,347. View filing ↗
- Section 08, Christopher Cain, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 205,672. View filing ↗
- Section 08, Mark Iwicki. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 26,250. View filing ↗
- Section 08, Allison Dorval. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 25,000. View filing ↗
- Section 08, Habib J. Dable. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 21,250. View filing ↗
- Section 08, Joshua Resnick, M.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 19,500. View filing ↗
- Section 08, David Grayzel, M.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 10,750. View filing ↗
- Section 08, Donald J. Santel. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 9,750. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 317,700 + equity 0 + all other 0 = 317,700, summed across the director compensation table rows.
- Janux Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Janux Therapeutics, Inc.'s own proxy. As printed: 13,506,231. View filing ↗
- Dianthus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Dianthus Therapeutics, Inc.'s own proxy. As printed: 10,614,702. View filing ↗
- Jade Biosciences, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Jade Biosciences, Inc.'s own proxy. As printed: 9,799,759. View filing ↗
- Cargo Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Cargo Therapeutics, Inc.'s own proxy. As printed: 9,300,120. View filing ↗
- Kymera Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Kymera Therapeutics, Inc.'s own proxy. As printed: 8,545,609. View filing ↗
- Spyre Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Spyre Therapeutics, Inc.'s own proxy. As printed: 6,707,361. View filing ↗
- Astria Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Astria Therapeutics, Inc.'s own proxy. As printed: 6,604,416. View filing ↗
- Alumis Inc., Section 10b CEO total. DEF 14A, filed 2026-05-18. CEO total compensation as printed in Alumis Inc.'s own proxy. As printed: 5,948,289. View filing ↗
- Pliant Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pliant Therapeutics, Inc.'s own proxy. As printed: 5,462,901. View filing ↗
- Zenas BioPharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Zenas BioPharma, Inc.'s own proxy. As printed: 4,661,000. View filing ↗
- Upstream Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Upstream Bio, Inc.'s own proxy. As printed: 4,302,100. View filing ↗
- Lyell Immunopharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Lyell Immunopharma, Inc.'s own proxy. As printed: 4,222,265. View filing ↗
- Prime Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Prime Medicine, Inc.'s own proxy. As printed: 3,894,187. View filing ↗
- Entrada Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Entrada Therapeutics, Inc.'s own proxy. As printed: 3,837,737. View filing ↗
- Contineum Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Contineum Therapeutics, Inc.'s own proxy. As printed: 3,409,448. View filing ↗
- Oruka Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Oruka Therapeutics, Inc.'s own proxy. As printed: 3,356,050. View filing ↗
- Kyverna Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Kyverna Therapeutics, Inc.'s own proxy. As printed: 1,814,980. View filing ↗
- Apogee Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Apogee Therapeutics, Inc.'s own proxy. As printed: 1,291,500. View filing ↗